Athera Biotechnologies develops drugs with the potential to improve treatment of patients with cardiovascular disease. The treatment concept is based on pioneering research results that highlight the link between low levels of specific biomarkers and the risk of developing atherosclerosis. Athera has identified, selected and patented the PC-mAb antibody that has been shown to have interesting biological and medicinal effects, and has also developed a robust production method.
The project is currently undergoing phase I trials in patients with severe peripheral artery disease who have undergone vein graft surgery. Athera has also developed a CE-approved test to identify those patients who are most likely to benefit from drug treatment using PC-mAb.
Athera Biotechnologies at a glance
What they do: Develops new drugs and diagnostic tools to prevent and treat cardiovascular diseases
Founded in: 2005
Head quarters: Stockholm, Sweden